Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome. (Q54432033)

29 May 2018

title

Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome. (English)

1 reference

29 May 2018

0 references

Lingyan Zheng

1

1 reference

29 May 2018

Zhiyuan Zhang

series ordinal

2

1 reference

29 May 2018

Chuangqi Yu

series ordinal

3

1 reference

29 May 2018

Chi Yang

series ordinal

4

1 reference

29 May 2018

publication date

1 June 2010

1 reference

29 May 2018

Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics

published in

1 reference

29 May 2018

volume

109

1 reference

29 May 2018

issue

6

1 reference

29 May 2018

page(s)

844-850

1 reference

29 May 2018

Sjögren's syndrome criteria

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Genetic aspects of Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Update in Sjögren syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

The possible etiopathogenic genes of Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Hepatitis C virus and Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Viruses contribute to the development of Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Evidence for coxsackievirus infection in primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Immunobiology of Toll-like receptors: emerging trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

The role of Toll-like receptors in the host response to viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Expression of interferon regulatory factor 1, 3, and 7 in primary Sjögren syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: Correlation with certain features of immune hyperactivity and factors associated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

Disproportion of helper T cell subsets in peripheral blood of patients with primary Sjögren's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIPLEO.2010.01.006

10.1016/J.TRIPLEO.2010.01.006

7 January 2021

Identifiers

DOI

1 reference

29 May 2018

PubMed ID

20399690

1 reference

29 May 2018